Kim Myung-sook named Novartis's Sebivo EGM leader

Novartis Korea said Kim Myung-sook, 37, a team leader of Novartis Korea' infection unit, was named a global crew leader (Head Center of Exellence) of Sebivo (telbivudine), a new hepatitis B virus (HBV) nucleoside analog polymerase inhibitor, in the emerging growth market (EGM).

Her EGM marketing leader nomination has been attributed to her outstanding marketing capability and to Novartis hea...